Hot Investor Mandate 1: Global Pharma Seeks Early Stage Therapeutic Platforms and Devices in Eye Diseases

18 Aug

A global pharmaceutical company headquartered in Japan with US offices specializes in ophthalmology and rheumatology medicines. The firm considers licensing later stage (Phase III and on) assets to enrich their pipeline, and support early stage biotech companies by co-investing with other venture firms where there is already a lead in place. The firm will initially invest $1-2 M, and up to $5 M throughout the life of the investment.

The firm is interested in research stage innovation in platform technologies, gene/cell therapies, device and drug delivery systems, bio markers, etc. Current areas of interests are: Retinal Disorders (Uveitis, Age-related macular degeneration, Diabetic macular edema), Glaucoma (Intraocular pressure reduction, Neuroprotection), and Corneal Disorders (Dry eye, Corneal epithelial defects). The firm’s European interests also includes orphan indications and drug delivery technologies.

The firm requires a lead venture firm to be in place before considering co-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: